Nature Medicine: Multi-antigen-targeting T cells in pediatric CNS tumors | Source Library

StudyPeer-reviewed research publisher

Source type: Study
Access type: Publisher
Publisher: Nature Medicine
Date: 2026-06-30
Added: 2026-06-30

Trust profile

VV Source Trust Matrix v1.0

VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.

Peer-reviewed research publisher

Publisher type: Peer-reviewed journal
Bias profile: Moderate

This source is strongest for clinical outcomes and mechanism and weaker for regulatory status and trial discovery.

VV Source Fit Score 1.0

Fit by use case

Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.

Frameworks ->

Regulatory status: 65/100; Context Source
Clinical outcomes: 92/100; Primary Anchor
Mechanism: 90/100; Primary Anchor
Safety: 86/100; Strong Support
Consumer context: 72/100; Context Source
Trial discovery: 65/100; Context Source

Best used for

Primary studies
Systematic reviews
Mechanistic research

Weak for

Regulatory status
Universal consumer recommendations

Used in Viral Vitalism

Primary sourcebrief1 reference

First-in-Human T-Cell Therapy Targets Three Proteins in Pediatric Brain Tumors

Roles: Primary source

Show section-level references

Researchers reported that systemically delivered autologous T cells targeting WT1, PRAME, and survivin met Phase 1 safety and feasibility endpoints in pediatric and young adult CNS tumor patients, with preliminary disease-control signals in some patients.

Related studies

No structured study record is currently attached to this source.